Capricor Therapeutics (CAPR) Stock Price, Quote, News & History | Benzinga

Capricor Therapeutics Inc (CAPR) Stock Price, Quote, News & History

CAPRNASDAQ

Trade with Public

Trade with Public

$9.89

-0.12-1.2%

At close: Sep 2, 5:00 PM EST

$9.92

0.030.3%

After Hours: 7:56 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$10.07

Close

$9.89

Volume / Avg.

5.17M / 5.98M

Day Range

$9.60 - $10.65

52 Wk Range

2.96 - 40.37

Market Cap

$576.74M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

33.72%

Days to Cover

1.64

Recent Capricor Therapeutics, Inc. News

Yext Posts Upbeat Q2 Earnings, Joins Fervo Energy, MiniMed Group And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were lower, with the Nasdaq Composite falling around 1% on Tuesday. Shares of Yext Inc (NYSE:YEXT) rose sharply after the company reported better-than-expected second-quarter earnings. The company also

Avi Kapoor

Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday

U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and more.

Avi Kapoor

Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday

Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.

Avi Kapoor

Why Is Capricor Therapeutics Stock Trading Higher on Monday?

Capricor stock rises as FDA extends its deramiocel review to Nov. 22 following new Phase 3 HOPE-3 data and an advisory panel setback.

Vandana Singh

Activist Investor Sounds Alarm on Capricor’s Cash Burn

Kaos Capital demands a governance reset and cash preservation at Capricor Therapeutics (NASDAQ: CAPR) as expenses rise.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-104.00M

Investing Cash Flow (TTM)

-144.36M

Financing Cash Flow (TTM)

246.05M

Free Cash Flow (TTM)

-129.78M

Capital Expenditure (TTM)

-25.78M

Net Change in Cash (TTM)

-2.31M

Analyst Trends and Forecast

4

Mar

1

May

3

Jul

1

Aug

1

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$435.37M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

2.36

Earnings Yield % (TTM)

-24.46%

Earnings Yield % (FWD)

-16.08%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$4.24

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$20.94M

Debt to Equity

0.37

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$10.07

Close

$9.89

Volume / Avg.

5.17M / 5.98M

Day Range

$9.60 - $10.65

52 Wk Range

2.96 - 40.37

Market Cap

$576.74M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

33.72%

Days to Cover

1.64

About

Sector

Health Care

Industry

Biotechnology

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in mu...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Capricor Therapeutics (CAPR) stock?

A

You can purchase shares of Capricor Therapeutics (NASDAQ:CAPR) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Capricor Therapeutics (CAPR) competitors?

A

Other companies in Capricor Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Capricor Therapeutics (CAPR) stock?

A

Capricor Therapeutics has a consensus price target of $36.86.

Q

What is the current price for Capricor Therapeutics (CAPR)?

A

The stock price for Capricor Therapeutics (NASDAQ: CAPR) is $9.92 last updated September 2, 2026 at 7:56 PM EDT.

Q

Does Capricor Therapeutics (CAPR) pay a dividend?

A

There are no upcoming dividends for Capricor Therapeutics.

Q

When is Capricor Therapeutics (NASDAQ:CAPR) reporting earnings?

A

Capricor Therapeutics does not have any upcoming earnings scheduled.

Q

Is Capricor Therapeutics (CAPR) going to split?

A

There is no upcoming split for Capricor Therapeutics.

Q

What sector and industry does Capricor Therapeutics (CAPR) operate in?

A

Capricor Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.